KPC Pharmaceuticals Inc Total Liabilities
KPC Pharmaceuticals Inc total liabilities. Based on the latest financial reports, KPC Pharmaceuticals Inc (600422) has total liabilities worth CN¥4.54 Billion CNY (≈ $664.77 Million USD) as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check financial resilience of KPC Pharmaceuticals Inc to evaluate the company's liquid asset resilience ratio.
Total Liabilities of KPC Pharmaceuticals Inc (1997–2025)
Total liabilities of KPC Pharmaceuticals Inc from 1997 to 2025. This chart illustrates how KPC Pharmaceuticals Inc's total liabilities have evolved over time, based on quarterly financial data. Explore how much of KPC Pharmaceuticals Inc's assets are long-term investments to see how much of total assets are deployed in long-term investments.
KPC Pharmaceuticals Inc Competitors by Total Liabilities
The table below lists competitors of KPC Pharmaceuticals Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Plejd AB (publ)
F:3CA
|
Germany | €346.32 Million |
|
Malakoff Corporation Bhd
KLSE:5264
|
Malaysia | RM13.53 Billion |
|
thyssenkrupp nucera AG & Co. KGaA
XETRA:NCH2
|
Germany | €447.70 Million |
|
Leedarson IoT Technology Inc
SHG:605365
|
China | CN¥2.70 Billion |
|
Jinzi Ham Co Ltd
SHE:002515
|
China | CN¥90.09 Million |
|
INVEX Controladora S.A.B. de C.V
MX:INVEXA
|
Mexico | MX$220.09 Billion |
|
Universal Corporation
NYSE:UVV
|
USA | $1.61 Billion |
|
Elopak AS
OL:ELO
|
Norway | Nkr724.99 Million |
Liability Composition Analysis (1997–2025)
This chart breaks down KPC Pharmaceuticals Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see balance sheet size of KPC Pharmaceuticals Inc.
Liquidity & Leverage Metrics
KPC Pharmaceuticals Inc Total Liabilities Ratios Explained
KPC Pharmaceuticals Inc total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.95 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.93 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.41 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how KPC Pharmaceuticals Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for KPC Pharmaceuticals Inc (1997–2025)
The table below shows the annual total liabilities of KPC Pharmaceuticals Inc from 1997 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | CN¥4.83 Billion ≈ $707.10 Million |
-17.61% |
| 2024-12-31 | CN¥5.87 Billion ≈ $858.25 Million |
+35.11% |
| 2023-12-31 | CN¥4.34 Billion ≈ $635.22 Million |
+1.20% |
| 2022-12-31 | CN¥4.29 Billion ≈ $627.68 Million |
+8.52% |
| 2021-12-31 | CN¥3.95 Billion ≈ $578.39 Million |
+12.31% |
| 2020-12-31 | CN¥3.52 Billion ≈ $515.01 Million |
+13.50% |
| 2019-12-31 | CN¥3.10 Billion ≈ $453.74 Million |
+5.36% |
| 2018-12-31 | CN¥2.94 Billion ≈ $430.67 Million |
+14.76% |
| 2017-12-31 | CN¥2.56 Billion ≈ $375.26 Million |
+43.25% |
| 2016-12-31 | CN¥1.79 Billion ≈ $261.97 Million |
+11.03% |
| 2015-12-31 | CN¥1.61 Billion ≈ $235.95 Million |
+65.48% |
| 2014-12-31 | CN¥974.40 Million ≈ $142.59 Million |
-3.20% |
| 2013-12-31 | CN¥1.01 Billion ≈ $147.31 Million |
-8.07% |
| 2012-12-31 | CN¥1.10 Billion ≈ $160.24 Million |
+53.72% |
| 2011-12-31 | CN¥712.37 Million ≈ $104.24 Million |
+19.56% |
| 2010-12-31 | CN¥595.84 Million ≈ $87.19 Million |
+17.80% |
| 2009-12-31 | CN¥505.79 Million ≈ $74.01 Million |
+3.97% |
| 2008-12-31 | CN¥486.48 Million ≈ $71.19 Million |
-12.34% |
| 2007-12-31 | CN¥554.98 Million ≈ $81.21 Million |
+1.94% |
| 2006-12-31 | CN¥544.44 Million ≈ $79.67 Million |
-16.28% |
| 2005-12-31 | CN¥650.31 Million ≈ $95.16 Million |
+44.92% |
| 2004-12-31 | CN¥448.75 Million ≈ $65.67 Million |
+56.49% |
| 2003-12-31 | CN¥286.76 Million ≈ $41.96 Million |
+49.26% |
| 2002-12-31 | CN¥192.11 Million ≈ $28.11 Million |
-5.94% |
| 2001-12-31 | CN¥204.24 Million ≈ $29.89 Million |
-15.31% |
| 2000-12-31 | CN¥241.15 Million ≈ $35.29 Million |
-18.03% |
| 1999-12-31 | CN¥294.19 Million ≈ $43.05 Million |
+10.99% |
| 1998-12-31 | CN¥265.06 Million ≈ $38.79 Million |
+53.98% |
| 1997-12-31 | CN¥172.13 Million ≈ $25.19 Million |
-- |
About KPC Pharmaceuticals Inc
KPC Pharmaceuticals,Inc., a pharmaceutical company, engages in the research and development, production, marketing, and commercial wholesale of botanical drugs and natural drugs in the People's Republic of China and internationally. It offers artemisia annua series, panax notoginseng, gastrodia, artemether, comether tablets, specialty herbal products, classic prescription for bones and joint, ant… Read more